DC Vaccine Technology

Dendritic cell (DC) is the representative antigen-presenting cells that act as command towers of the human immune system. DC exerts immune-surveillance for exogenous and endogenous pathogens and activates T lymphocytes giving rise to various immunological responses. Furthermore DC is involved in the pathophysiology of several diseases such as cancer, infectious disease, or autoimmune diseases, but they can also be used as therapeutic tools in these conditions.

CreaVax is the DC therapy brand name of JW CreaGene and generated from patient’s own monocytes in specialized method of JW CreaGene. When the enforced DCs are injected into the patient, they migrate to lymph node, educate T cells to recognize cancer cells, and induce activation and proliferation of T cells. Finally, the activated T cells move to tumor site to kill cancer cells. And released antigens from dying cancer cells can induce secondary immune responses. Furthermore, DC vaccination induces memory T cells and these T cells help to prevent cancer recurrence.